- Home
- QS vs HCM Comparison
QS vs HCM Comparison
Compare QS & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- HCM
- Stock Information
- Founded
- QS 2010
- HCM 2000
- Country
- QS United States
- HCM Hong Kong
- Employees
- QS N/A
- HCM N/A
- Industry
- QS Auto Parts:O.E.M.
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- HCM Health Care
- Exchange
- QS Nasdaq
- HCM Nasdaq
- Market Cap
- QS 2.2B
- HCM 2.5B
- IPO Year
- QS N/A
- HCM N/A
- Fundamental
- Price
- QS $3.99
- HCM $14.54
- Analyst Decision
- QS Sell
- HCM Hold
- Analyst Count
- QS 7
- HCM 1
- Target Price
- QS $5.19
- HCM $19.00
- AVG Volume (30 Days)
- QS 8.4M
- HCM 99.5K
- Earning Date
- QS 04-23-2025
- HCM 03-19-2025
- Dividend Yield
- QS N/A
- HCM N/A
- EPS Growth
- QS N/A
- HCM N/A
- EPS
- QS N/A
- HCM 0.04
- Revenue
- QS N/A
- HCM $630,201,000.00
- Revenue This Year
- QS N/A
- HCM $14.86
- Revenue Next Year
- QS N/A
- HCM $19.54
- P/E Ratio
- QS N/A
- HCM $68.17
- Revenue Growth
- QS N/A
- HCM N/A
- 52 Week Low
- QS $3.40
- HCM $11.51
- 52 Week High
- QS $9.52
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- QS 49.96
- HCM 48.47
- Support Level
- QS $3.77
- HCM $14.24
- Resistance Level
- QS $4.12
- HCM $15.52
- Average True Range (ATR)
- QS 0.17
- HCM 0.57
- MACD
- QS 0.03
- HCM 0.01
- Stochastic Oscillator
- QS 55.83
- HCM 42.98
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.